1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,300 | 14,500 | 02.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| Do | Pharming Group N.V.: Pharming Group announces the filing of its 2025 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 27.03. | Pharming granted EU backing for rare immunodeficiency therapy | 2 | Seeking Alpha | ||
| 27.03. | Pharming Group N.V.: Pharming Group receives positive CHMP opinion for Joenja (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older | 943 | GlobeNewswire (Europe) | If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision... ► Artikel lesen | |
| 24.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.03. | Pharming Group N.V.: Pharming Group announces approval of Joenja (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older | 188 | GlobeNewswire (Europe) | First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 12.03. | Pharming outlines $405M-$425M 2026 revenue target as Joenja and RUCONEST drive growth | 9 | Seeking Alpha | ||
| 12.03. | Wainwright bekräftigt "Kaufen"-Rating für Pharming-Aktie dank stabilem Wachstum | 5 | Investing.com Deutsch | ||
| 12.03. | Wainwright reiterates Pharming stock Buy rating on commercial growth | 2 | Investing.com | ||
| 12.03. | Pharming Group meldet Umsatz von 106,5 Mio. US-Dollar im 4. Quartal und bestätigt Prognose für 2026 | 14 | Investing.com Deutsch | ||
| 12.03. | Pharming beats top-line estimates; introduces FY26 outlook | 2 | Seeking Alpha | ||
| 12.03. | Pharming Group N.V. Bottom Line Climbs In Q4 | 1 | RTTNews | ||
| 12.03. | Pharming Group N.V.: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow | 718 | GlobeNewswire (Europe) | Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST and rising demand for Joenja (leniolisib) Fourth quarter 2025 total revenues increased by 15%... ► Artikel lesen | |
| 03.03. | Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? | 2 | Zacks | ||
| 26.02. | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 | 908 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| 17.02. | Pharming Group N.V.: Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | 521 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 17, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer 36th Annual... ► Artikel lesen | |
| 03.02. | Pharming Group N.V.: Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day | 874 | GlobeNewswire (Europe) | Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces... ► Artikel lesen | |
| 02.02. | With FDA rejections, Aquestive's shares go up, while Pharming's go down | 16 | FiercePharma | ||
| 02.02. | FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients | 13 | Benzinga.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,20 | +0,13 % | Biotech vor der nächsten Phase - BioNTech, Newron und Bioxyne im Check | ||
| VALNEVA | 2,746 | +0,44 % | Valneva: Wahrscheinlichkeit für Zulassung sinkt | Ein von Valneva und Pfizer entwickelter Lyme-Borreliose-Impfstoffkandidat (LB6V) hat in einer Phase-III-Studie den primären statistischen Endpunkt nicht erreicht. Die Aktie hat mit einem deutlichen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,950 | -2,56 % | Kapitalerhöhung mit Verwässerungseffekt: Inovio-Aktie stürzt ab | ||
| BAVARIAN NORDIC | 26,140 | +0,11 % | Bavarian Nordic A/S: Bavarian Nordic - Transactions in Connection with Share Buy-Back Program | ||
| INTELLIA THERAPEUTICS | 11,300 | -0,70 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| KUROS BIOSCIENCES | 25,500 | -1,01 % | Kuros schreibt 2025 schwarze Zahlen | Schlieren - Das Biotechunternehmen Kuros hat Wort gehalten und den Umsatz 2025 um mehr als 70 Prozent gesteigert. Getragen wurde die Entwicklung erneut durch das Knochenersatzprodukt MagnetOs. Konkret... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,184 | +1,56 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| XOMA ROYALTY | 28,600 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| ATAIBECKLEY | 3,220 | -2,42 % | Psychedelika-Investments im Aufwind: Emyria Limited und AtaiBeckley forcieren neue PTBS-Therapiestandards | ||
| PHARMING | 1,422 | -1,04 % | Pharming Group N.V. - 6-K, Report of foreign issuer | ||
| BIOMERIEUX | 92,60 | -0,59 % | BioMerieux SA Profit Declines In Full Year | PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,742 | -5,07 % | CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress | ||
| AC IMMUNE | 2,450 | +2,08 % | AC Immune SA: AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update | AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's... ► Artikel lesen | |
| MOLECULAR PARTNERS | 3,375 | -5,46 % | MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer | ||
| ESPERION | 2,284 | +0,75 % | Esperion Therapeutics, Inc.: Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) | - Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued... ► Artikel lesen |
PHARMING GROUP NV ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+0,74 %) liegt der Kurs bei 13,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.